2018
DOI: 10.1002/rmv.1976
|View full text |Cite
|
Sign up to set email alerts
|

A review on current status of antiviral siRNA

Abstract: Viral diseases like influenza, AIDS, hepatitis, and Ebola cause severe epidemics worldwide. Along with their resistant strains, new pathogenic viruses continue to be discovered so creating an ongoing need for new antiviral treatments. RNA interference is a cellular gene-silencing phenomenon in which sequence-specific degradation of target mRNA is achieved by means of complementary short interfering RNA (siRNA) molecules. Short interfering RNA technology affords a potential tractable strategy to combat viral pa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
67
0
2

Year Published

2018
2018
2024
2024

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 98 publications
(73 citation statements)
references
References 164 publications
1
67
0
2
Order By: Relevance
“…Cells transfected with siRNAs or expressing an shRNA targeting viral genomes display sequence‐specific reductions in viral RNA accumulation and virus replication upon challenge with homologous viruses, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), influenza A virus (IAV), West Nile virus (WNV), SARS coronavirus, human papilloma virus and various picornaviruses (Gitlin et al, ; Jacque et al, ; Lee et al, ; Ge et al, ; Kapadia et al, ; Konishi et al, ; Randall et al, ; Lu et al, ; Phipps et al, ; Takigawa et al, ; Bitko et al, ; Shi et al, ; Sim et al, ; Werk et al, ; Yuan et al, ; Kumar et al, ; Bousarghin et al, ; Qureshi et al, ). Similarly, delivery of siRNAs to mice, prior to or concomitant with viral challenge, provides protection against infection with various viruses (Ge et al, ; Giladi et al, ; McCaffrey et al, ; Tompkins et al, ; Bitko et al, ; Tan et al, ; Shah & Schaffer, ).…”
Section: Viral Determinants Of Antiviral Rnaimentioning
confidence: 99%
“…Cells transfected with siRNAs or expressing an shRNA targeting viral genomes display sequence‐specific reductions in viral RNA accumulation and virus replication upon challenge with homologous viruses, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), influenza A virus (IAV), West Nile virus (WNV), SARS coronavirus, human papilloma virus and various picornaviruses (Gitlin et al, ; Jacque et al, ; Lee et al, ; Ge et al, ; Kapadia et al, ; Konishi et al, ; Randall et al, ; Lu et al, ; Phipps et al, ; Takigawa et al, ; Bitko et al, ; Shi et al, ; Sim et al, ; Werk et al, ; Yuan et al, ; Kumar et al, ; Bousarghin et al, ; Qureshi et al, ). Similarly, delivery of siRNAs to mice, prior to or concomitant with viral challenge, provides protection against infection with various viruses (Ge et al, ; Giladi et al, ; McCaffrey et al, ; Tompkins et al, ; Bitko et al, ; Tan et al, ; Shah & Schaffer, ).…”
Section: Viral Determinants Of Antiviral Rnaimentioning
confidence: 99%
“…GS-5734, a nucleotide prodrug, showed broad-spectrum anti-coronavirus activity against bat CoV, pre-pandemic bat CoV, and existing human CoV in vitro and over primary human lung epithelial cell cultures and was found promising for treating epidemic and zoonotic coronaviruses of the near future (Sheahan et al, 2017). The siRNA or antisense oligonucleotides (ASO) can be used to combat the virus by targeting its genome (Qureshi et al, 2018).…”
Section: Oligonucleotides Targeting Sars-cov-2 Rna Genomementioning
confidence: 99%
“…In the process, small interfering RNAs (siRNAs) play a crucial role in amplification and maintenance of the silencing response through loading onto Argonaute proteins, which uses siRNAs to target and cleave homologous viral RNAs (Chiu and Rana, 2003). As such, RNAi has become a powerful research tool for studies of gene function and siRNA‐based antiviral therapies (Tuschl and Borkhardt, 2002; Small, 2007; Badia et al , 2017; Ghosh et al , 2017; Qureshi et al , 2018).…”
Section: Introductionmentioning
confidence: 99%